0A6R Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strategic Merger And FundingThe proposed merger could materially improve the combined company’s funding visibility and broaden its development platform through North Immunology’s NOR-101 program. The expected financing supports multi-year clinical execution, reducing near-term dependence on repeated capital raises if the transaction closes.
Clinical And Biomarker ProgressProgress into the final oncology cohort and directional biomarker changes provide evidence that the Hemopurifier mechanism is generating measurable biological signals. Persistence to eight weeks strengthens the development rationale, although the findings still require formal analysis and validation.
Expense Control And LiquidityLower operating expenses and recently improved cash resources extend the time available to complete current clinical work and analyze results. This disciplined spending can preserve development capacity, reduce immediate financing pressure, and give management more flexibility while pursuing partnerships or larger studies.
Bears Say
Pre-revenue Financial ModelThe company lacks a recurring commercial revenue base and remains far from breakeven, so ongoing research and clinical activity is funded mainly through external capital. Persistent cash losses limit financial flexibility and make future progress dependent on successful financing or commercialization.
Limited Clinical ValidationSmall, preliminary cohorts cannot establish safety, efficacy, reproducibility, or broader clinical relevance. Until formal statistical analysis and larger studies are completed, the Hemopurifier’s commercial and regulatory potential remains uncertain, increasing the risk that early signals do not translate into meaningful outcomes.
Substantial Shareholder DilutionThe transaction substantially reduces existing Aethlon holders’ ownership of the future combined business, shifting control and economic participation to North Immunology shareholders and investors. Although the financing improves resources, the ownership structure limits legacy holders’ share of future upside and remains subject to closing approvals.
Aethlon Medical News
0A6R FAQ
What was Aethlon Medical Inc’s price range in the past 12 months?
Currently, no data Available
What is Aethlon Medical Inc’s market cap?
Aethlon Medical Inc’s market cap is €9.03M.
When is Aethlon Medical Inc’s upcoming earnings report date?
Aethlon Medical Inc’s upcoming earnings report date is Nov 18, 2026 which is in 48 days.
How were Aethlon Medical Inc’s earnings last quarter?
Aethlon Medical Inc released its earnings results on Aug 13, 2026. The company reported -€3.549 earnings per share for the quarter, missing the consensus estimate of -€3.465 by -€0.084.
Is Aethlon Medical Inc overvalued?
According to Wall Street analysts Aethlon Medical Inc’s price is currently Undervalued.
Does Aethlon Medical Inc pay dividends?
Aethlon Medical Inc does not currently pay dividends.
What is Aethlon Medical Inc’s EPS estimate?
Aethlon Medical Inc’s EPS estimate is -2.38.
How many shares outstanding does Aethlon Medical Inc have?
Currently, no data Available
What happened to Aethlon Medical Inc’s price movement after its last earnings report?
Aethlon Medical Inc reported an EPS of -€3.549 in its last earnings report, missing expectations of -€3.465. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Aethlon Medical Inc?
Currently, no hedge funds are holding shares in GB:0A6R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aethlon Medical Inc
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
0A6R Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced tangible near-term progress with clear caveats. Positives include advancement into the final clinical cohort, encouraging Cohort 2 biomarker signals, a peer-reviewed Long COVID preclinical publication, ongoing R&D expansion, an improved post-quarter cash position following a ~$4.0M financing, and an 11.9% reduction in operating expenses. Key negatives are that clinical observations are preliminary and based on very small sample sizes, statistical analyses are pending, dosing is logistically constrained, and larger trials will require additional capital or partnerships. Overall, the company shows disciplined resource management and meaningful early scientific signals but faces validation, scale and funding headwinds before efficacy or regulatory clarity can be established.View all GB:0A6R earnings summaries